

Press Release

N°: 2007/2

from [Neurotune AG](#)

Neurotune announces closing of 3rd Seed Financing Round

With the conclusion of its third Seed Round Financing Neurotune adds another CHF 3.3 Mio to its funds.

Schlieren, April 13th 2007. Neurotune AG is glad to announce today the latest capital increase. During the recent financing round management was able to raise another CHF 3.3 Mio in equity from existing and new investors. The total capital raised in equity and other funds so far compounds to more than CHF 13 Mio.

The current financial resources will be dedicated to lead Neurotune's activities, i.e. its research and discovery program into optimization of promising compounds and preclinical development.

Contact:

Mrs. Theres Oesch
Assistant to the CEO

neurotune ag

Waghstrasse 27

8952 Schlieren (Zurich)

Switzerland

URL www.neurotune.com

Phone +41 44 200 21 95

Fax +41 44 200 20 10

theres.oesch@neurotune.com

About Neurotune AG

Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has its seat in Schlieren (Zurich), Switzerland.

Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy - Sarcopenia, second priority to drugs for rehabilitation therapies after stroke or traumatic brain injury, and third priority is given to drugs for treatment of other CNS disturbances.

About Sarcopenia

With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy –Sarcopenia - is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.

The treatment of Sarcopenia is a growing market with no available causal treatment.

* * * * *

This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the Neurotunes' shelf registration statement and the registered direct offering. For further information regarding these and other risks related to Neurotunes' business, investors should consult Neurotune.

* * * * *